Chemokines and defensins as HIV suppressive factors: An evolving story

Current Pharmaceutical Design

Volumn 13, Issue 2, 2007, Pages 163-172

  Garzino Demo, Alfredo ^a  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

defensins; AIDS; CCR5; HIV; MDC; MIP ; MIP 1 ; RANTES

Indexed keywords

BETA DEFENSIN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LIGAND; MICROBICIDE; RANTES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DEATH; DISEASE COURSE; EPITHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNIZATION; INFECTION CONTROL; INNATE IMMUNITY; LYMPHOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; VIRUS ISOLATION;

ANIMALS; CHEMOKINES; DEFENSINS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 33846151995     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313696     Document Type: Review

References (184)

1. Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease. Immunol Rev 1997; 159: 31-48.
2. Beattie T, Rowland-Jones S, Kaul R. HIV-1 and AIDS: what are protective immune responses? J HIV Ther 2002; 7(2): 35-9.
3. Paxton WA, Dragic T, Koup RA, Moore JP. The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. AIDS Res Hum Retroviruses 1996; 12(13): 1203-7.
4. Lopalco L, Pastori C, Barassi C, Furci L, Burastero S, Lillo F, et al. Heterogeneity in exposed uninfected individuals. J Biol Regul Homeost Agents 1997; 11(1-2): 27-31.
5. Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J (Clin Res Ed) 1983; 287(6407): 1754-7.
6. Kernoff PB, Lee CA, Karayiannis P, Thomas HC. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60(3): 469-79.
7. Fabio G, Smeraldi RS, Gringeri A, Marchini M, Bonara P, Mannucci PM. Susceptibility to HIV infection and AIDS in Italian haemophiliacs is HLA associated. Br J Haematol 1990; 75(4): 531-6.
8. Young TP. Immune mechanisms in HIV infection. J Assoc Nurses AIDS Care 2003; 14(6): 71-5.
9. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234(4783): 1563-6.
10. Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 1989; 66(4): 628-30.
11. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991; 87(4): 1462-6.
12. Blackbourn DJ, Mackewicz CE, Barker E, Hunt TK, Herndier B, Haase AT, et al. Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinicai state of HIV-infected individuals. Proc Natl Acad Sci USA 1996; 93(23): 13125-30.
13. Gomez AM, Smaill FM, Rosenthal KL. Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease. Clin Exp Immunol 1994; 97(1): 68-75.
14. Kannagi M, Masuda T, Hattori T, Kanoh T, Nasu K, Yamamoto N, et al. Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro. J Virol 1990; 64(7): 3399-406.
15. Ennen J, Findeklee H, Dittmar MT, Norley S, Ernst M, Kurth R. CD8+ T lymphocytes of African green monkeys secrete an immunodeficiency virus-suppressing lymphokine. Proc Natl Acad Sci USA 1994; 91(15): 7207-11.
16. Rosok B, Voltersvik P, Larsson BM, Albert J, Brinchmann JE, Asjo B. CD8+ T cells from HIV type 1-seronegative individuals suppress vinis replication in acutely infected cells. AIDS Res Hum Retroviruses 1997; 13(1): 79-85.
17. Chen CH, Weinhold KJ, Bartlett JA, Bolognesi DP, Greenberg ML. CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses. 1993; 9(11): 1079-86.
18. Chun TW, Justement JS, Moir S, Hallahan CW, Ehler LA, Liu S, et al. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci USA 2001; 98(1): 253-8.
19. Yang OO, Kalams SA, Trocha A, Cao H, Luster A, Johnson RP, et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997; 71(4): 3120-8.
20. Mosoian A, Teixeira A, Caron E, Piwoz J, Klotman ME. CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. Viral Immunol 2000; 13(4): 481-95.
21. Mackewicz CE, Blackbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995; 92(6): 2308-12.
22. Chang TL, Mosoian A, Pine R, Klotman ME, Moore JP. A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. J Virol 2002; 76(2): 569-81.
23. Copeland KF, Leith JG, McKay PJ, Rosenthal KL. CD8+ T cell supernatants of HIV type 1-infected individuals have opposite effects on long terminal repeat-mediated transcription in T cells and monocytes. AIDS Res Hum Retroviruses. 1997; 13(1): 71-7.
24. Mackewicz CE, Patterson BK, Lee SA, Levy JA. CD8(+) cell noncytotoxic anti-human immunodeficiency virus response inhibits expression of viral RNA but not reverse transcription or provirus integration. J Gen Virol 2000; 81 (Pt 5): 1261-4.
25. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270(5243): 1811-5.
26. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272(5263): 872-7.
27. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85(7): 1135-48.
28. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272(5270): 1955-8.
29. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion co-factors. Cell 1996; 85(7): 1149-58.
30. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381(6584): 667-73.
31. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381(6584): 661-6.
32. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2(11): 1240-3.
33. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273(5283): 1856-62.
34. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382(6593): 722-5.
35. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86(3): 367-77.
36. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3(1): 23-36.
37. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3(10): 1160-2.
38. Katzenstein TL, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen AK, et al. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16(1): 10-4.
39. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. Aids 1997; 11(3): 305-10.
40. Meyer L, Magierowska M, Hubert JB, Rouzioux C, Deveau C, Sanson F, et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. Aids 1997; 11 (11): F73-8.
41. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127(10): 882-90.
42. Smith O. HIV CCR5 resistance incomplete. Nat Med 1997; 3(4): 372-3.
43. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997; 349(9060): 1219.
44. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997; 349(9060): 1219-20.
45. Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62(6): 2026-32.
46. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989; 63(5): 2118-25.
47. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66(3): 1354-60.
48. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1 - infected individuals. J Exp Med 1997; 185(4): 621-8.
49. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996; 93(26): 15382-7.
50. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71(10): 7478-87.
51. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3(11): 1259-65.
52. Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, et al. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20(2): 115-21.
53. Jansson M, Backstrom E, Bjorndal A, Holmberg V, Rossi P, Fenyo EM, et al. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol 1999; 2(6): 325-38.
54. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Aids 1999; 13(11): 1305-11.
55. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkan DA. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 2000; 271(2): 253-8.
56. Morris L, Cilliers T, Bredell H, Phoswa M, Martin DJ. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 2001; 17(8): 697-701.
57. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreccptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
58. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4(1): 72-7.
59. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96(10): 5698-703.
60. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, et al. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000; 43(10): 2049-63.
61. Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, et al. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob Agents Chemother 2001; 45(12): 3538-43.
62. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al. SCHC (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98(22): 12718-23.
63. Billick E, Seibert C, Pugach P, Ketas T, Trkola A, Endres MJ, et al. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J Virol 2004; 78(8): 4134-44.
64. Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338(1): 182-99.
65. Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. Aids 2005; 19(14): 1443-1448.
66. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Methods 2005; 11(11): 1170-2.
67. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95(7): 3857-61.
68. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998; 177(2): 331-6.
69. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2(4): 412-7.
70. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998; 244(1): 66-73.
71. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999; 96(21): 11986-91.
72. Cocchi F, DeVico AL, Yarchoan R, Redfield & Cleghorn F, Blattner WA, et al. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000; 97(25): 13812-7.
73. Tartakovsky B, Burke M, Vardinon N, Rosenberg F, Hatiashvili D, Turner D, et al. Increased intracellular macrophage inflammatory protein-1beta correlates with advanced HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19(1): 1-5.
74. Wasik TJ, Bratosiewicz J, Wierzbicki A, Whiteman VE, Rutstein RR, Starr SE, et al. Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol 1999; 162(7): 4355-64.
75. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997; 186(3): 455-60.
76. Ferbas J, Giorgi JV, Amini S, Grovit-Ferbas K, Wiley DJ, Detels R, et al. Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta in vitro is a correlate of reduced human immunodeficiency virus burden in vivo. J Infect Dis 2000; 182(4): 1247-50.
77. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307(5714): 1434-40.
78. Sun L, Abdelwahab SF, Lewis GK, Garzino-Demo, A. Recall antigen activation induces prompt release of CCR5 ligands from PBMC: implication in memory responses and immunization. Int Immunol 2004; 16(11): 1623-31.
79. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173(9): 5372-80.
80. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417(6884): 95-8.
81. Abdelwahab SF, Cocchi F, Bagley KC, Kamin-Lewis R, Gallo RC, DeVico A, et al. HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci USA 2003; 100(25): 15006-10.
82. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997; 278(5338): 695-8.
83. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P. Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progressor patients. Aids 1996; 10(12): 1431-2.
84. Weiss L, Si-Mohamed A, Giral P, Castiel P, Ledur A, Blondin C, et al. Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997; 176(6): 1621-4.
85. Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A. Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 1998; 26(2): 100-3.
86. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr. Serum chemokine levels in patients with non-progressing HIV infection. Aids 1996; 10(9): F29-33.
87. Krowka JF, Gesner ML, Ascher MS, Sheppard HW. Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 1997; 85(1): 21-7.
88. Kakkanaiah VN, Ojo-Amaize EA, Peter JB. Concentrations of circulating beta-chemokines do not correlate with viral load in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998; 5(4): 499-502.
89. Polo S, Veglia F, Malnati MS, Gobbi C, Farci P, Raiteri R, et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. Aids 1999; 13(4): 447-54.
90. Detheux M, Standker L, Vakili J, Munch J, Forssmann U, Adermann K, et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 2000; 192(10): 1501-8.
91. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99(1): 395-400.
92. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78(6): 2790-807.
93. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003; 100(18): 10411-6.
94. Garzino-Demo A, DeVico AL, Cocchi F, Gallo RC. Betachemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 1998; 14(Suppl 2): S177-84.
95. Garzino-Demo A, DeVico AL, Gallo RC. Chemokine receptors and chemokines in HIV infection. J Clin Immunol 1998; 18(4): 243-55.
96. Stott EJ, Schild GC. Strategies for AIDS vaccines. J Antimicrob Chemother 1996; 37(Suppl B): 185-98.
97. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, et al. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Dev Biol Stand 1998; 92: 225-35.
98. Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De Giuli Morghen C, Radaelli A, et al. beta-chemokines and neutralizing anti-body titers correlate with sterilizing immurtity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 1998; 95(18): 10803-8.
99. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2(7): 767-75.
100. Ahmed RK, Makitalo B, Karlen K, Nilsson C, Biberfeld G, Thorstensson R. Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol 2002; 129(1):11-8.
101. Wang Y, Underwood J, Vaughan R, Harmer A, Doyle C, Lehner T. Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 IRV-1 in women. Clin Exp Immunol 2002; 129(3): 493-501.
102. Wang Y, Tao L, Mitchell E, Bravery C, Berlingieri P, Armstrong P, et al. Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat Med 1999; 5(9): 1004-9.
103. Bergmeier LA, Babaahmady K, Wang Y, Lehner T. Mucosal alloimmunization elicits T-cell proliferation, CC chemokines, CCR5 antibodies and inhibition of simian immunodeficiency virus infectivity. J Gen Virol 2005; 86(Pt 8): 2231-8.
104. Lehner T, Bergmeier LA, Wang Y, Tao L, Sing M, Spallek R, et al. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 2000; 30(2): 594-603.
105. Frauenschuh A, DeVico AL, Lim SP, Gallo RC, Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 2004; 23(4): 546-54.
106. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16(4): 187-91.
107. Borkow G, Bentwich Z. Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries. Clin Diagn Lab Immunol 2002; 9(3): 505-7.
108. Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank J, Pope M, et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses 2003; 19(3): 177-86.
109. Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, et al. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 2004; 78(14): 7602-9.
110. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, et al. Prevention of vaginal SHIV transmission in rhesus. macaques through inhibition of CCR5. Science 2004; 306(5695): 485-7.
111. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol 2004; 2(5): 401-13.
112. Nizet V, Obtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414(6862): 454-7.
113. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415(6870): 389-95.
114. Hancock RE, Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16(2): 82-8.
115. Ganz T, Lehrer RI. Antimicrobial peptides of vertebrates. Curr Opin Immunol 1998; 10(1): 41-4.
116. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14(1): 96-102.
117. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991; 251(5000): 1481-5.
118. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim A Chertov O, et al. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 2000; 275(42): 32911-8.
119. Hoover DM, Cherlov O, Lubkowski J. The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. J Biol Chem 2001; 276(42): 39021-6.
120. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB Jr, et al. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem 2002; 277(10): 8279-89.
121. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002; 99(4): 1813-8.
122. Cole AM, Lehrer RI. Minidefensins: antimicrobial peptides with activity against HIV-1. Curr Pharm Des 2003; 9(18): 1463-73.
123. Ganz T, Seisted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76(4): 1427-35.
124. Wilde CG, Griffith JE, Marra MN, Suable JL, Scott RW. Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J Biol Chem 1989; 264(19): 11200-3.
125. Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI. Primary structures of three human neutrophil defensins. J Clin Invest 1985; 76(4): 1436-9.
126. Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992; 267(32): 23216-25.
127. Jones DE, Bevins CL. Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett 1993; 315(2): 187-92.
128. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000; 1(2): 113-8.
129. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306(2): 257-64.
130. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276(8): 5707-13.
131. Schutte BC, McCray PB Jr. [beta]-defensins in lung host defense. Annu Rev Physiol 2002; 64: 709-48.
132. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: a novel beta-defensin from human plasma. FEBS Lett 1995; 368(2): 331-5.
133. Zhao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396(2-3): 319-22.
134. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature 1997; 387(6636): 861.
135. Jia HP, Schulte BC, Schudy A, Linzmeier R, Guthmiller JM, Johnson GK, et al. Discovery of new human beta-defensins using a genomics-based approach. Gene 2001; 263(1-2): 211-8.
136. Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ, et al. Discovery of five conserved beta -defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002; 99(4): 2129-33.
137. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298(5595): 995-1000.
138. Zhang L, Lopez P, He T, Yu W, Ho DD. Retraction of an interpretation. Science 2004; 303(5657): 467.
139. Nakashima H, Yamamoto N, Masuda M, Fujii N. Defensins inhibit HIV replication in vitro. Aids 1993; 7(8): 1129.
140. Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al. Localized antimicrobial peptide expression in human gingiva. J Periodomal Res 2001; 36(5): 285-94.
141. Dunsche A, Acil Y, Siebert R, Harder J, Schroder JM, Jepsen S. Expression profile of human defensins and antimicrobial proteins in oral tissues. J Oral Pathol Med 2001; 30(3): 154-8.
142. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, et al. Human beta-defensins suppress HIV infection: potential role in mucosal protection. J Virol In Press.
143. Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, et al Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; 67(6): 2740-5.
144. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002; 110(2): 121-4.
145. Abiko Y, Suraweera AK, Nishimura M, Arakawa T, Takuma T, Mizoguchi I, et al. Differential expression of human beta-defensin 2 in keratinized and non-keratinized oral epithelial lesions; immunohistochemistry and in situ hybridization. Virchows Arch 2001; 438(3): 248-53.
146. Sawaki K, Mizukawa N, Yamaai T, Fukunaga J, Sugahara T. Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. Oral Dis 2002; 8(1): 37-41.
147. Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect Immun 1998; 66(9): 4222-8.
148. Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA. Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun 2000; 68(5): 2907-15.
149. Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect Immun 2004; 72(1): 352-8.
150. Joly S, Maze C, McCray PB Jr. and Guthmiller JM. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 2004; 42(3): 1024-9.
151. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {betal}-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55(6): 888-96.
152. Vankeerberghen A, Nuytten H, Dierickx K, Quirynen M, Cassiman JJ, Cuppens H. Differential induction of human Beta-defensin expression by periodontal commensals and pathogens in periodontal pocket epithelial cells. J Periodontol 2005; 76(8): 1293-303.
153. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 2003; 17(16): F39-48.
154. Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003; 170(9): 4708-16.
155. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173(1): 515-20.
156. Leikina E, Delanoe-Ayari H, Melikov K, Cho MS, Chen A, Waring AJ, et al. Carbobydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005; 6(10): 995-1001.
157. Chang TL, Francois F, Mosoian A, Klotman ME. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol 2003; 77(12): 6777-84.
158. Chang TL, Vargas J Jr, DelPortillo A, Klotman ME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005; 115(3): 765-73.
159. Baba TW, Koch J, Mittler ES, Greene M, Wyand M, Penninck D, et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994; 10(4): 351-7.
160. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267(5205): 1820-5.
161. Baba TW, Trichel AM, An L, Liska V, Martin LN, Murphey-Corb M, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 1996; 272(5267): 1486-9.
162. Ruprecht RM, Baba TW, Liska V, Ayehunie S, Andersen J, Montefiori DC, et al. Oral SIV, SHIV, and HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14(Suppl 1): S97-103.
163. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5(2): 194-203.
164. Ruprecht RM, Baba TW, Liska V, Ray NB, Martin LN, Murphey-Corb M, et al. Oral transmission of primate lentiviruses. J Infect Dis 1999; 179(Suppl 3): S408-12.
165. Fox PC, Wolff A, Yeh CK, Atkinson JC, Baum BJ. Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men, women, and children. J Am Dent Assoc 1989; 118(6): 709-11.
166. Archibald DW, Cole GA. In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res Hum Retroviruses 1990; 6(12): 1425-32.
167. Shine N, Konopka K, Duzgunes N. The anti-HIV-1 activity associated with saliva. J Dent Res 1997; 76(2): 634-40.
168. Malamud D, Nagashunmugam T, Davis C, Kennedy S, Abrams WR, Kream R, et al. Inhibition of HIV infectivity by human saliva. Oral Dis 1997; 3(Suppl 1): S58-63.
169. Kennedy S, Davis C, Abrams WR, Billings PC, Nagashunmugam T, Friedman H, et al. Submandibular salivary proteases: lack of a role in anti-HIV activity. J Dent Res 1998; 77(7): 1515-9.
170. Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999; 179(Suppl 3): S431-5.
171. Konopka K, Shine N, Pretzer E, Duzgunes N. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity. J Dent Res 1999; 78(12): 1773-6.
172. Robinovitch MR, Ashley RL, Iversen JM, Vigoren EM, Oppenheim FG, Lamkin M. Parotid salivary basic proline-rich proteins inhibit HIV-I infectivity. Oral Dis 2001; 7(2): 86-93.
173. Skott P, Lucht E, Ehnlund M, Bjorling E. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Oral Dis 2002; 8(3): 160-7.
174. Shugars DC, Sweet SP, Malamud D, Kazmi SH, Page-Shafer K, Challacombe SJ. Saliva and inhibition of HIV-1 infection: molecular mechanisms. Oral Dis 2002; 8(Suppl 2): 169-75.
175. Su H, Boackle RJ. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva. Mol Immunol 1991; 28(8): 811-7.
176. Malamud D, Davis C, Berthold P, Roth E, Friedman H. Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses 1993; 9(7): 633-7.
177. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96(1): 456-64.
178. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T. Human beta-defensin- 1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101(8): 1633-42.
179. Iqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, Embree JE, et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005; 192(5): 728-38.
180. Sawaki K, Mizukawa N, Yamaai T, Yoshimoto T, Nakano M, Sugahara T. High concentration of beta-defensin-2 in oral squamous cell carcinoma. Anticancer Res 2002; 22(4): 2103-7.
181. Shi J, Zhang G, Wu H, Ross C, Blecha F, Ganz T. Porcine epithelial beta-defensin 1 is expressed in the dorsal tongue at antimicrobial concentrations. Infect Immun 1999; 67(6): 3121-7.
182. Alfano M, Rizzi C, Corti D, Adduce L, Poli G. Bacterial toxins: potential weapons against HIV infection. Curr Pharm Des 2005; 11(22): 2909-26.
183. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11(14): 1805-43.
184. Pohlmann S, Reeves JD. Cellular entry of HIV: Evaluation of therapeutic targets. Curr Pharm Des 2006; 12(16): 1963-73.